To amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish drug adherence guidelines, and for other purposes.
- Bill Number
- H.R. 1142
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-02-07: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2025-06-04T19:11:16Z
AI-Generated Summary
Purpose
This bill, H.R. 1142, aims to improve medication adherence among Medicare beneficiaries by requiring the Secretary of Health and Human Services (HHS) to create guidelines that target 90% adherence rates for certain drugs covered under Medicare Parts B and D. It seeks to use modern technology and cost-effective drug options to enhance patient compliance and health outcomes.
Key Provisions
- Establishment of Guidelines: The HHS Secretary must develop drug adherence guidelines focused on achieving 90% adherence for Medicare Part B drugs (medications or biological products paid for under Medicare's outpatient services) and Medicare Part D drugs (prescription drugs covered under Medicare's outpatient prescription drug benefit).
- Incorporation of Technology: The guidelines must integrate artificial intelligence (AI) and machine learning (advanced computer systems that learn from data to make predictions or recommendations) to support adherence efforts.
- Promotion of Affordable Options: To the greatest extent possible, the guidelines should encourage the use of generic drugs (lower-cost versions of brand-name drugs) and biosimilar drugs (lower-cost alternatives to biologic medicines, which are complex drugs derived from living organisms).
- Definitions: The bill defines key terms, such as Medicare Part B drugs and Medicare Part D drugs, by referencing existing laws under the Social Security Act.
Significant Changes to Existing Law
- Adds a new section (Section 1712) to Title XVII of the Public Health Service Act (a major U.S. law governing public health programs).
- This is the primary change, as it introduces a federal mandate for HHS to create and implement these specific adherence guidelines, which did not previously exist in this form. No other parts of existing law are directly altered.
Potential Impacts
- On Government Agencies: HHS will need to allocate resources for developing and updating the guidelines, potentially involving collaboration with tech experts and pharmaceutical reviewers. This could lead to new programs or tools within Medicare administration.
- On Citizens: Medicare beneficiaries (primarily older adults and people with disabilities) may benefit from better tools and reminders to take medications as prescribed, potentially improving health and reducing hospital visits. It could also lower out-of-pocket costs through greater use of generics and biosimilars.
- On International Relations: No direct impacts, as the bill focuses on domestic U.S. healthcare policy.
- Broader effects might include cost savings for the Medicare program (estimated to cover over 65 million Americans), reducing overall healthcare spending by minimizing waste from non-adherence.
Main Stakeholders Affected
- HHS and Medicare Administrators: Responsible for creating and enforcing the guidelines.
- Medicare Beneficiaries: The primary group targeted, as the guidelines aim to help them stick to their prescriptions.
- Pharmaceutical Industry: Companies producing generics and biosimilars may see increased demand, while brand-name drug makers could face competition.
- Healthcare Providers: Doctors, pharmacists, and clinics may need to adopt AI tools or new practices to promote adherence.
- Technology Firms: Providers of AI and machine learning solutions could gain opportunities to partner with HHS.
Notable Legal, Constitutional, or Political Implications
- Legal: The bill builds on existing authorities under the Public Health Service Act and Social Security Act without expanding HHS powers in controversial ways. It may require future rulemaking (HHS creating detailed rules) to implement, which could face standard administrative review.
- Constitutional: No apparent challenges; it involves federal spending and regulation of interstate commerce in healthcare, which falls under Congress's established authority.
- Political: Emphasizes efficiency and innovation in Medicare, a politically sensitive program due to its size and cost. It could appeal across party lines by addressing rising drug costs and patient health, but implementation might spark debates over AI privacy or the role of government in promoting specific drugs.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Schweikert, David [R-AZ-1]
Recent Actions
- 2025-02-07: Referred to the House Committee on Energy and Commerce.
- 2025-02-07: Introduced in House
- 2025-02-07: Introduced in House
Bill Versions
- To amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish drug adherence guidelines, and for other purposes. — issued 2025-02-07 — PDF (2 pages)